Severe drought in Argentina temporarily interrupted growth trajectory; decline in Argentina partially offset by higher sales in North America
HB4 Wheat outperformed top commercial varieties, on average, across all environments with a 43% yield increase in targeted conditions
Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced financial results for the fiscal second quarter ended December 31, 2022. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted.
FINANCIAL & BUSINESS HIGHLIGHTS
- Historical drought during 2Q23 in Argentina slashed wheat output by 50% countrywide and delayed soybean and corn planting. Planting progress for soybeans lagged by 20-to-30 percentage points as compared with the historical average for the entire optimal planting window.
- Total revenues in 2Q23 were $94.4 million, a 7% decrease compared with the pro forma revenues for the second quarter of last year, which include historical revenues from Pro Farm. Sales growth in North America partially offset the decline in Argentina.
- Adjusted EBITDA for the quarter was $10.3 million and was primarily affected by a decline in gross profit contribution from sales in Argentina.
- Under severe drought conditions HB4 Wheat showed higher yields than conventional varieties across all environments, with an average 43% yield improvement in targeted environments. Seed inventories and product performance are on track to meet FY23 expectations.
- HB4 Soy is on track despite unusually difficult planting conditions in Argentina. Half of the current seed multiplication area has been planted with new generation varieties. HB4 Soy program was launched with growers in Brazil.
- Trigall Genetics (a Bioceres joint venture) closed the 80% acquisition of wheat breeding assets in Australia.
MANAGEMENT REVIEW
Mr. Federico Trucco, Bioceres´ Chief Executive Officer, commented: “As we anticipated during our prior earnings call, our growth momentum has been transiently interrupted by unusually severe drought conditions in Argentina, which extended throughout the entire planting window for summer crops. Although we are flat when compared with last year’s revenue for the quarter, we are down by 7% year-over-year for this three-month period on a pro forma basis after including Pro Farm’s operations. This circumstantial decline interrupts a run of seven consecutive quarters of top-line growth and profitability expansion, which we expect to resume in the second half of the fiscal year as weather conditions have turned more favorable in our key commercial regions.”
“On a less circumstantial and more permanent front, the severe drought conditions in Argentina have allowed us to put HB4 technology to the test, like never before. The performance of HB4 wheat has been outstanding on all fronts. In environments yielding less than 2 tons per hectare, HB4 wheat has outperformed commercial materials by an average yield improvement of 43%, winning in seven out of every 10 locations and, averaging a win rate of eight out of 10 when aggregating the last three seasons. When confounding effects from background genetics are neutralized ‒ as is the case for comparisons among isogenic varieties (i.e. varieties that are nearly genetically identical except for the presence of the HB4 gene) ‒ HB4 win rates increase to above 80%, across all environments, not just those with yields below 2 tons per hectare, ratifying the broad hectare opportunity resulting from the technology.”
“From an HB4 wheat inventories perspective, we can cover up to one-third of next season’s HB4 plantings with second generation materials, allowing us to replace first generation varieties almost fully by FY24, when we expect HB4 wheat to deliver $15-to-$20 million in incremental EBITDA. As a reminder, second-generation materials show a double-digit genetic gain when compared with first-generation materials in high-yielding environments, outperforming top commercial varieties even when yields average more than 4 tons per hectare.”
Mr. Enrique Lopez Lecube, Bioceres´ Chief Financial Officer, noted, “While our fiscal second quarter results were adversely affected by the severe drought in Argentina, we also saw the benefit of strategic actions that drove our positive performance for the first half of 2023 and will benefit our results going forward. Our priorities to diversify our product portfolio, expand our geographic presence and maintain a strong alliance with our grower customers – all with an eye on managing costs – will allow us to continue the momentum we saw in the first half of the year, and drive further Adjusted EBITDA improvement. Moving forward, we believe the extreme weather conditions we are seeing around the world highlight the increasing need for our products. While weather may temporarily affect our quarterly results from time to time, our long-term growth trajectory remains robust.”
KEY FINANCIAL METRICS
(In millions of U.S. dollars, unless where otherwise stated)
Table 1: 2Q23 & 1H23 Key Financial Metrics |
||||||
2Q22
|
2Q23 |
% Change |
1H22
|
1H23 |
% Change |
|
Revenue by Segment |
|
|
|
|
|
|
Crop Protection |
56.3 |
53.3 |
(5%) |
97.3 |
116.3 |
20% |
Seed and Integrated Products |
15.3 |
16.3 |
7% |
24.0 |
30.2 |
26% |
Crop Nutrition |
29.5 |
24.7 |
(16%) |
54.3 |
75.0 |
38% |
Total Revenue |
101.1 |
94.4 |
(7%) |
175.6 |
221.5 |
26% |
Gross Profit |
48.7 |
35.3 |
(28%) |
82.6 |
86.7 |
5% |
Gross Margin |
48.1% |
37.4% |
(1,076 bps) |
45.5% |
40.5% |
(505 bps) |
2Q22
|
2Q23 |
% Change |
1H22
|
1H23 |
% Change |
|
Adjusted EBITDA |
18.3 |
10.3 |
(43%) |
30.8 |
34.9 |
13% |
1. |
2Q22 and 1H22 pro forma financials include Pro Farm historical numbers. |
Summary: Drought in Argentina drove the decline in 2Q23 Crop Protection and Crop Nutrition revenues, partially offset by moderate growth in the Seed and Integrated Products segment, which included first-time HB4 Soy sales. Lower sales in Argentina were partially offset by growth in other Latin American geographies. Additionally, Pro Farm biological products delivered higher sales in North America in the quarter, diversifying the product portfolio internationally and in new product markets. Some 2Q23 sales were realized in 1Q23 as commercial teams in Argentina locked-in early sales to distributors and growers in anticipation of challenging weather conditions. As a result, while revenues for 2Q23 decreased 7%, sales for 1H23 increased 26%. Overall gross profit declined 27% in the quarter, a function of product mix and lower pricing for key products in Argentina, where the commercial strategy focused on increasing farmer proximity and preserving market share. Lower sales and gross margins resulted in a lower Adjusted EBITDA of $10.3 million. For the first half of FY23, gross profit was up 5% and Adjusted EBITDA, at $34.9 million, was 13% higher year-over-year on a pro forma basis.
For a full version of Bioceres fiscal second quarter 2023 earnings release, click here.
SECOND QUARTER 2023 EARNINGS CONFERENCE CALL
Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company’s website.
To access the call, please use the following information:
Date: |
Thursday, February 9, 2023 |
|
Time: |
8:30 a.m. EST, 5:30 a.m. PST |
|
Toll Free dial-in number: |
1-844-200-6205 |
|
Toll/International dial-in number: |
1-929-526-1599 |
|
Conference ID: |
689739 |
|
Webcast: |
Click here |
Please dial in 5-10 minutes prior to the start time to register and join.
The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website here.
A replay of the call will be available through February 14, 2023, following the conference.
Toll Free Replay Number: |
1-866-813-9403 |
|
International Replay Number: |
+44 204 525 0658 |
|
Replay ID: |
195470 |
About Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. Through its HB4® program, the company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit here.
Forward-Looking Statements
This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data and, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses by governments, clients and the company, on our business, financial condition, liquidity position and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful, (ii) the uncertainty related to COVID-19 in the farming community will be short lived, and (iii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the impact of COVID-19 on the company’s business, operations, liquidity and financial results and the other factors that are described in the sections entitled “Risk Factors” in the company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.
Unaudited Consolidated Statement of Comprehensive Income (Figures in U.S. dollars) |
||
|
Three-month period
|
Three-month period
|
Total revenue |
94,410,185 |
92,662,853 |
Cost of sales |
(59,138,119) |
(55,332,989) |
Gross profit |
35,272,066 |
37,329,864 |
% Gross profit |
37% |
40% |
Operating expenses |
(32,424,008) |
(20,198,593) |
Share of profit of JV |
40,048 |
1,141,323 |
Other income or expenses, net |
(669,137) |
(571,365) |
Operating profit |
2,218,969 |
17,701,229 |
Financial result |
(9,963,524) |
(8,221,621) |
Profit/(loss) before income tax |
(7,744,555) |
9,479,608 |
Income tax |
(615,529) |
(4,141,102) |
Profit/(loss) for the period |
(8,360,084) |
5,338,506 |
Other comprehensive profit/(loss) |
585,883 |
7,893,351 |
Total comprehensive profit/(loss) |
(7,774,201) |
13,231,857 |
|
|
|
Profit/(loss) for the period attributable to: |
|
|
Equity holders of the parent |
(8,662,197) |
3,427,093 |
Non-controlling interests |
(550,212) |
3,427,093 |
|
(9,212,409) |
6,854,186 |
Total comprehensive profit/(loss) attributable to: |
|
|
Equity holders of the parent |
(8,285,010) |
3,427,093 |
Non-controlling interests |
(341,516) |
3,157,855 |
|
(8,626,526) |
6,584,948 |
Weighted average number of shares |
|
|
Basic |
62,710,957 |
41,104,331 |
Diluted |
62,710,957 |
42,403,196 |
Unaudited Consolidated Statement of Financial Position (Figures in U.S. dollars) |
||
ASSETS |
12/31/2022 |
06/30/2022 |
CURRENT ASSETS |
|
|
Cash and cash equivalents |
68,550,022 |
33,475,266 |
Other financial assets |
18,882,388 |
5,401,133 |
Trade receivables |
178,230,222 |
111,752,310 |
Other receivables |
25,653,800 |
19,327,584 |
Income and minimum presumed income taxes recoverable |
1,674,314 |
1,647,398 |
Inventories |
157,647,583 |
126,044,122 |
Biological assets |
581,100 |
57,313 |
Total current assets |
451,219,429 |
297,705,126 |
NON-CURRENT ASSETS |
|
|
Other financial assets |
1,104,718 |
619,841 |
Trade receivables |
- |
200,412 |
Other receivables |
3,173,261 |
2,254,199 |
Income and minimum presumed income taxes recoverable |
18,465 |
44,412 |
Deferred tax assets |
4,619,306 |
4,011,374 |
Investments in joint ventures and associates |
38,810,692 |
38,554,092 |
Property, plant and equipment |
63,794,675 |
49,908,325 |
Intangible assets |
174,412,251 |
76,704,869 |
Goodwill |
122,532,487 |
36,073,685 |
Right-of-use leased asset |
13,164,994 |
12,144,026 |
Total non-current assets |
421,630,849 |
220,515,235 |
Total assets |
872,850,278 |
518,220,361 |
LIABILITIES |
12/31/2022 |
06/30/2022 |
CURRENT LIABILITIES |
|
|
Trade and other payables |
160,017,912 |
125,849,620 |
Borrowings |
105,462,623 |
71,301,468 |
Employee benefits and social security |
9,867,633 |
7,619,121 |
Deferred revenue and advances from customers |
61,233,268 |
5,895,313 |
Income tax payable |
1,012,347 |
7,538,764 |
Consideration for acquisition |
1,943,216 |
3,048,562 |
Lease liabilities |
3,007,806 |
1,412,904 |
Total current liabilities |
342,544,805 |
222,665,752 |
NON-CURRENT LIABILITIES |
|
|
Trade and other payables |
810,921 |
- |
Borrowings |
79,109,119 |
74,177,169 |
Investments in joint ventures and associates |
122,059 |
717,948 |
Deferred tax liabilities |
46,130,828 |
29,005,943 |
Provisions |
5,543,219 |
603,022 |
Consideration for acquisitions |
8,467,428 |
9,854,228 |
Convertible notes |
72,558,213 |
12,559,071 |
Lease liability |
10,880,795 |
10,338,380 |
Total non-current liabilities |
223,622,582 |
137,255,761 |
Total liabilities |
566,167,387 |
359,921,513 |
EQUITY |
|
|
Equity attributable to owners of the parent |
272,692,323 |
127,358,573 |
Non-controlling interests |
33,990,568 |
30,940,275 |
Total equity |
306,682,891 |
158,298,848 |
Total equity and liabilities |
872,850,278 |
518,220,361 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208006033/en/
Contacts
Bioceres Crop Solutions
Paula Savanti
Head of Investor Relations
investorrelations@biocerescrops.com